20 postdoc-computational-biomedical-engineering PhD positions at University of Cambridge
Sort by
Refine Your Search
-
both sites. The project sits at the interface of cell line engineering, protein science and machine learning and you will receive advanced training in these areas while developing methods to accelerate
-
The Centre for Doctoral Training in Nanoscience and Nanotechnology (NanoDTC) at the University of Cambridge invites applications for its 3.5-year interdisciplinary PhD programme. The programme
-
on sustainable design and low carbon materials. Ramboll is a global engineering, architecture and consultancy company and Buro Happold is an international, integrated consultancy of engineers, designers and
-
, interdisciplinary research group, including a postdoc, DTP students, and technicians. Training will include fieldwork, bird handling, ringing, lab techniques in molecular biology, microbiome sequencing
-
chromatin profiling methods along with CRISPR/Cas9-meduated cell line engineering and various animal models. You will study the effects of the activation or depletion of chromatin-modifying enzymes using
-
cancer, novel genetically engineered mouse models for the depletion of different CAF populations, in vitro three-dimensional pancreatic tumour organoid/fibroblast co-culture models, CRISPR-based
-
preferably at Masters level in Civil Engineering and a strong interest in cementitious materials and experimental work. Fully-funded studentships (fees and maintenance) are only available for eligible home
-
equivalent standard from an overseas university, in a relevant subject such as Physics, Chemistry, Materials Science, Chemical Engineering. Full details of the University's entrance requirements and
-
, and simulations across physics, chemistry, and engineering. Applicants should have, or be expected to gain, a high (1st or 2:1) honours degree in Physics or Chemistry. Fixed-term: The funds
-
Supervisors: Professor Sir Steve Jackson and Dr Mark O'Connor (AZ Partner) Course start date: 1st October 2026 Project details Targeted Alpha Therapy (TAT) selectively delivers high Linear Energy Transfer (LET) alpha-particles to cancer cells, maximising efficacy while minimising toxicity. ...